These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37734837)

  • 1. Validation of the ΔSUV
    Itti E; Blanc-Durand P; Berriolo-Riedinger A; Kanoun S; Kraeber-Bodéré F; Meignan M; Gat E; Gouill SL; Casasnovas RO; Bodet-Milin C
    J Nucl Med; 2023 Nov; 64(11):1706-1711. PubMed ID: 37734837
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
    J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
    Itti E; Meignan M; Berriolo-Riedinger A; Biggi A; Cashen AF; Véra P; Tilly H; Siegel BA; Gallamini A; Casasnovas RO; Haioun C
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of Dmax and %ΔSUVmax of
    Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
    BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
    Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
    Eertink JJ; Burggraaff CN; Heymans MW; Dührsen U; Hüttmann A; Schmitz C; Müller S; Lugtenburg PJ; Barrington SF; Mikhaeel NG; Carr R; Czibor S; Györke T; Ceriani L; Zucca E; Hutchings M; Kostakoglu L; Loft A; Fanti S; Wiegers SE; Pieplenbosch S; Boellaard R; Hoekstra OS; Zijlstra JM; de Vet HCW
    Blood Adv; 2021 May; 5(9):2375-2384. PubMed ID: 33944897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.
    Casasnovas RO; Ysebaert L; Thieblemont C; Bachy E; Feugier P; Delmer A; Tricot S; Gabarre J; Andre M; Fruchart C; Mounier N; Delarue R; Meignan M; Berriolo-Riedinger A; Bardet S; Emile JF; Jais JP; Haioun C; Tilly H; Morschhauser F
    Blood; 2017 Sep; 130(11):1315-1326. PubMed ID: 28701367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim PET in Diffuse Large B-Cell Lymphoma.
    Kurch L; Hüttmann A; Georgi TW; Rekowski J; Sabri O; Schmitz C; Kluge R; Dührsen U; Hasenclever D
    J Nucl Med; 2021 Aug; 62(8):1068-1074. PubMed ID: 33246974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
    Casasnovas RO; Meignan M; Berriolo-Riedinger A; Bardet S; Julian A; Thieblemont C; Vera P; Bologna S; Brière J; Jais JP; Haioun C; Coiffier B; Morschhauser F;
    Blood; 2011 Jul; 118(1):37-43. PubMed ID: 21518924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUV
    Texte E; Lequesne J; Tilly H; Jardin F; Vera P; Stamatoullas A; Becker S
    Leuk Lymphoma; 2021 May; 62(5):1088-1097. PubMed ID: 33289431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.
    Itti E; Lin C; Dupuis J; Paone G; Capacchione D; Rahmouni A; Haioun C; Meignan M
    J Nucl Med; 2009 Apr; 50(4):527-33. PubMed ID: 19289424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
    Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim FDG
    Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.